- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
insitro Completes Pioneering AI Study on Brown Fat
Biotech firm shares new genetic targets for potential therapies
Feb. 2, 2026 at 6:15pm
Got story updates? Submit your updates here. ›
insitro, a leading artificial intelligence-driven biotechnology company, has announced the completion of its first AI-enabled human genetics study focused on brown adipose tissue, also known as brown fat. The study has identified several differentiated genetic targets that could lead to new therapeutic approaches for metabolic conditions.
Why it matters
Brown fat plays a crucial role in regulating metabolism and energy expenditure, making it an important area of research for potential treatments of obesity, diabetes, and other metabolic disorders. insitro's use of AI to analyze human genetics data represents a novel approach that could accelerate the discovery of new drug targets.
The details
The study leveraged insitro's proprietary AI platform to analyze genetic data from thousands of individuals, identifying several promising targets for further investigation. These targets are differentiated from those previously identified through traditional research methods, potentially offering new avenues for therapeutic development.
- The study was completed in February 2026.
The players
insitro
A leading artificial intelligence-driven biotechnology company focused on developing new treatments for complex diseases.
What they’re saying
“This study represents a significant milestone for insitro and the broader field of AI-enabled drug discovery. By leveraging our unique capabilities, we've identified several promising genetic targets that could lead to new therapies for metabolic conditions.”
— Daphne Koller, Founder and CEO of insitro
The takeaway
insitro's pioneering use of AI to analyze human genetics data has the potential to accelerate the discovery of new drug targets for metabolic disorders, demonstrating the power of technology-driven approaches in the biotech industry.
